Replies to post #109314 on Regen BioPharma Inc (RGBP)

[Schuller]

I doubt a buyout on patents alone. They have proof of concept on some of those so that is what's very valuable.

Real value for shareholders is when they get IND approval and get their 2(or3) IND's into the lab. Lab results sell the company.

If they had funding in 2016 the mRNA results recently could easily have been Regen.

There's still plenty time. Debt first.